Peter L Havens1, Charles B Stephensen2, Marta D Van Loan2, Gertrud U Schuster3, Leslie R Woodhouse2, Patricia M Flynn4, Catherine M Gordon5, Cynthia G Pan1, Brandy Rutledge6, D Robert Harris6, Georgine Price6, Alyne Baker7, William A Meyer8, Craig M Wilson9, Rohan Hazra10, Bill G Kapogiannis10, Kathleen Mulligan11. 1. Department of Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee. 2. Agricultural Research Service, Western Human Nutrition Research Center, US Department of Agriculture, Davis. 3. Department of Nutrition, University of California, Davis. 4. Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Pediatrics, University of Cincinnati College of Medicine/Cincinnati Children's Hospital Medical Center, Ohio. 6. Westat, Rockville, Maryland. 7. Tulane University of Health Sciences Center, New Orleans, Louisiana. 8. Quest Diagnostics, Baltimore, Maryland. 9. Department of Epidemiology, University of Alabama at Birmingham. 10. Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland. 11. Department of Medicine, Division of Endocrinology, Zuckerberg San Francisco General Hospital, University of California, San Francisco.
Abstract
Background: Tenofovir disoproxil fumarate (TDF) decreases bone mineral density (BMD). We hypothesized that vitamin D3 (VITD3) would increase BMD in youth receiving TDF. Methods: This was a randomized, double-blind, placebo-controlled trial of directly observed VITD3 vs placebo every 4 weeks for 48 weeks in youth aged 16-24 years with HIV, RNA load <200 copies/mL, takingTDF-containing combination antiretroviral therapy (TDF-cART) for ≥180 days. Participants (N = 214) received a daily multivitamin containing VITD3 400 IU and calcium 162 mg, plus monthly randomized VITD3 50000 IU (n = 109) or placebo (n = 105). Outcome was change from baseline to week 48 in lumbar spine BMD (LSBMD). Data presented are median (Q1, Q3). Results:Participants were aged 22.0 (21.0, 23.0) years, 84% were male, and 74% were black/African American. At baseline, 62% had 25-hydroxy vitamin D (25-OHD) <20 ng/mL. Multivitamin adherence was 49% (29%, 69%), and VITD3/placebo adherence 100% (100%, 100%). Vitamin D intake was 2020 (1914, 2168) and 284 (179, 394) IU/day, and serum 25-OHDconcentration was 36.9 (30.5, 42.4) and 20.6 (14.4, 25.8) ng/mL at 48 weeks in VITD3 and placebo groups, respectively (P < .001). From baseline to week 48, LSBMD increased by 1.15% (-0.75% to 2.74%) in the VITD3 group (n = 99; P < .001) and 0.09% (-1.49% to 2.61%) in the placebo group (n = 89; P = .25), without between-group difference (P = .12). VITD3 group changes occurred with baseline 25-OHD <20 ng/mL (1.17% [-.82% to 2.90%]; P = .004) and ≥20 ng/mL (0.93% [-.26% to 2.15%]; P = .033). Conclusions: For youth taking TDF-cART, LSBMD increased through 48 weeks with VITD3 plus multivitamin, but not with placebo plus multivitamin, independent of baseline vitamin D status. Clinical Trials Registration: NCT01751646.
RCT Entities:
Background: Tenofovir disoproxil fumarate (TDF) decreases bone mineral density (BMD). We hypothesized that vitamin D3 (VITD3) would increase BMD in youth receiving TDF. Methods: This was a randomized, double-blind, placebo-controlled trial of directly observed VITD3 vs placebo every 4 weeks for 48 weeks in youth aged 16-24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy (TDF-cART) for ≥180 days. Participants (N = 214) received a daily multivitamin containing VITD3 400 IU and calcium 162 mg, plus monthly randomized VITD3 50000 IU (n = 109) or placebo (n = 105). Outcome was change from baseline to week 48 in lumbar spine BMD (LSBMD). Data presented are median (Q1, Q3). Results:Participants were aged 22.0 (21.0, 23.0) years, 84% were male, and 74% were black/African American. At baseline, 62% had 25-hydroxy vitamin D (25-OHD) <20 ng/mL. Multivitamin adherence was 49% (29%, 69%), and VITD3/placebo adherence 100% (100%, 100%). Vitamin D intake was 2020 (1914, 2168) and 284 (179, 394) IU/day, and serum 25-OHD concentration was 36.9 (30.5, 42.4) and 20.6 (14.4, 25.8) ng/mL at 48 weeks in VITD3 and placebo groups, respectively (P < .001). From baseline to week 48, LSBMD increased by 1.15% (-0.75% to 2.74%) in the VITD3 group (n = 99; P < .001) and 0.09% (-1.49% to 2.61%) in the placebo group (n = 89; P = .25), without between-group difference (P = .12). VITD3 group changes occurred with baseline 25-OHD <20 ng/mL (1.17% [-.82% to 2.90%]; P = .004) and ≥20 ng/mL (0.93% [-.26% to 2.15%]; P = .033). Conclusions: For youth taking TDF-cART, LSBMD increased through 48 weeks with VITD3 plus multivitamin, but not with placebo plus multivitamin, independent of baseline vitamin D status. Clinical Trials Registration: NCT01751646.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Mar Masiá; Sergio Padilla; Catalina Robledano; Natividad López; José Manuel Ramos; Felix Gutiérrez Journal: AIDS Res Hum Retroviruses Date: 2011-07-19 Impact factor: 2.205
Authors: Heidi J Kalkwarf; Vicente Gilsanz; Joan M Lappe; Sharon Oberfield; John A Shepherd; Thomas N Hangartner; Xangke Huang; Margaret M Frederick; Karen K Winer; Babette S Zemel Journal: J Clin Endocrinol Metab Date: 2010-03-01 Impact factor: 5.958
Authors: Peter L Havens; Rohan Hazra; Charles B Stephensen; Jennifer J Kiser; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan Journal: Antivir Ther Date: 2014-02-17
Authors: Lisa Hamzah; Juan M Tiraboschi; Helen Iveson; Martina Toby; Christine Mant; John Cason; Keith Burling; Emily Wandolo; Isabelle Jendrulek; Chris Taylor; Fowzia Ibrahim; Ranjababu Kulasegaram; Alastair Teague; Frank A Post; Julie Fox Journal: Antivir Ther Date: 2015-10-13
Authors: Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.771
Authors: Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister Journal: Lancet Infect Dis Date: 2015-11-02 Impact factor: 25.071
Authors: Risa M Hoffman; Caitlin Newhouse; Brian Chu; Jeffrey S A Stringer; Judith S Currier Journal: Curr HIV/AIDS Rep Date: 2021-01-05 Impact factor: 5.071
Authors: Denise L Jacobson; Jane C Lindsey; Catherine Gordon; Rohan Hazra; Hans Spiegel; Flavia Ferreira; Fabiana R Amaral; Jesica Pagano-Therrien; Aditya Gaur; Kathy George; Jane Benson; George K Siberry Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Peter L Havens; Suzanne E Perumean-Chaney; Amit Patki; Stacey S Cofield; Craig M Wilson; Nancy Liu; Peter L Anderson; Raphael J Landovitz; Bill G Kapogiannis; Sybil G Hosek; Kathleen Mulligan Journal: Clin Infect Dis Date: 2020-02-03 Impact factor: 9.079
Authors: Justin Penner; Rashida A Ferrand; Ceri Richards; Kate A Ward; James E Burns; Celia L Gregson Journal: PLoS One Date: 2018-11-15 Impact factor: 3.240
Authors: Sebastian Noe; Christine I Moeckel; Christiane Schwerdtfeger; Celia Oldenbuettel; Hans Jaeger; Eva Wolf; Christoph D Spinner Journal: Interdiscip Perspect Infect Dis Date: 2018-09-02
Authors: Sebastian Noe; Silke Heldwein; Carmen Wiese; Rita Pascucci; Ariane von Krosigk; Farhad Schabaz; Celia Jonsson-Oldenbuettel; Hans Jaeger; Eva Wolf Journal: Adv Pharmacol Sci Date: 2018-12-31